There are currently 625 clinical trials in Austin, Texas looking for participants to engage in research studies. Trials are conducted at various facilities, including GSK Investigational Site, Dell Childrens Medical Center of Central Texas, Pfizer Investigational Site and University of Texas at Austin. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Sequential Multiple Assignment Randomized Trial for Bipolar Depression
NCT06433635
Recruiting
This is a sequential multiple assignment randomized trial for adults (ages \> 18) with a bipolar disorder type 1 diagnosis currently experiencing a depressive episode. It is a randomized pragmatic trial that will compare four commonly prescribed treatments for bipolar depression, which includes three FDA-approved medications (Cariprazine, Quetiapine and Lurasidone) and one antipsychotic/antidepressant combination (Aripiprazole/Escitalopram).
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
05/21/2025
Locations: University of Texas at Austin, Austin, Texas
Conditions: Bipolar I Disorder, Depression
Register for Updates
A Study of GC012F (AZD0120), a CAR T Therapy Targeting CD19 and BCMA in Subjects With Relapsed/Refractory Multiple Myeloma
NCT05850234
Recruiting
This trial is a phase 1b/2, open-label, multicenter study of GC012F (AZD0120), a CD19/BCMA dual CART-cell therapy, in adult subjects with relapsed/refractory Multiple Myeloma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/20/2025
Locations: Research Site, Austin, Texas
Conditions: Relapsed/ Refractory Multiple Myeloma
Register for Updates
PAS-004 in Patients With Advanced Solid Tumors
NCT06299839
Recruiting
The main purpose of this clinical trial is to test PAS-004 in people with advanced solid tumors with rat sarcoma virus (RAS), neurofibromatosis type I (NF1), or rapidly accelerated fibrosarcoma (RAF) mutations. The main questions it aims to answer are: * How well participants are able tolerate different doses of PAS-004, and * What side effects PAS-004 might have. Study participants will have regular visits to the study doctor and be asked to have tests and exams done to check on their health... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/20/2025
Locations: NEXT Oncology, Austin, Texas
Conditions: RAS Mutation, NF1 Mutation, RAF Mutation, Advanced Solid Tumors
Register for Updates
Study of Sacituzumab Govitecan in Participants With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment
NCT04617522
Recruiting
The goals of this clinical study are to learn more about the safety and dosing of the study drug, sacituzumab govitecan-hziy, in participants with solid tumors and moderate liver problems.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/19/2025
Locations: NEXT Austin, Austin, Texas
Conditions: Advanced or Metastatic Solid Tumor, Liver Failure
Register for Updates
DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma
NCT04696029
Recruiting
Difluoromethylornithine (DFMO) will be used in an open label, multicenter, study as Maintenance Therapy for Molecular High Risk/Very High Risk and Relapsed/Refractory Medulloblastoma.
Gender:
ALL
Ages:
21 years and below
Trial Updated:
05/19/2025
Locations: Dell Children's Blood and Cancer Center, Austin, Texas
Conditions: Medulloblastoma
Register for Updates
Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease
NCT06456593
Recruiting
This study has 3 treatment phases, a 12-Week Induction Phase, a 40-Week Maintenance Phase, and a 48-Week Extension Phase. The objective is to evaluate the efficacy and safety of obefazimod compared to placebo as induction and maintenance therapy in subjects with moderately to severely active CD after inadequate response (no response, loss of response, or intolerance) to conventional therapies and/or advanced therapies. The primary objective for the 48-Week Extension Phase is to evaluate the sa... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
05/19/2025
Locations: Central Texas Clinical Research, LLC, Austin, Texas
Conditions: Moderately to Severely Active Crohn Disease
Register for Updates
A 2-part Study Consisting of a Multiple Ascending Dose Safety Study in Participants With Macular Edema Following Branch Retinal Vein Occlusion and a Dose-finding Safety and Preliminary Efficacy Study in Participants With Either Diabetic Macular Edema or Neovascular Age-related Macular Degeneration
NCT06664502
Recruiting
EYE-TIE-201 is a 2-part study to investigate the safety and effectiveness of a new drug being developed called EYE201. All participants in the study will receive a total of 3 injections of EYE201 into the study eye, spaced at 4 weeks apart. In the first part, termed the multiple ascending dose (MAD) portion of study, the safety of EYE201 will be assessed at increasing doses in branch retinal vein occlusion (BRVO) participants. Approximately 12 participants will be entered in this part of the s... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/19/2025
Locations: Austin, Texas, Austin, Texas
Conditions: Diabetic Macular Edema (DME), Neovascular Age-related Macular Degeneration (NVAMD), BRVO - Branch Retinal Vein Occlusion
Register for Updates
A Study to Find and Confirm the Dose and Assess Safety, Reactogenicity and Immune Response of a Vaccine Against Pandemic H5N1 Influenza Virus in Healthy Younger and Older Adults
NCT06382311
Recruiting
The aim of this study is to evaluate the safety, reactogenicity and immunogenicity of the Flu Pandemic messenger RNA (mRNA) vaccine (including dose-finding and dose-confirmation) administered in healthy adults 18 to 85 years of age.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
05/18/2025
Locations: GSK Investigational Site, Austin, Texas
Conditions: Influenza, Human
Register for Updates
The Pediatric Anesthesia Quality Improvement Project
NCT00674388
Recruiting
The Study is designed to collect information about adverse events that occur in children undergoing anesthesia in participating hospitals. Demographic information will be collected on all anesthetics. An analysis of each adverse event will be performed and entered into the database. From this information we will devise strategies to prevent these adverse events.
Gender:
ALL
Ages:
21 years and below
Trial Updated:
05/15/2025
Locations: Dell Children's Medical Center of Central Texas, Austin, Texas
Conditions: Surgery, Anesthesia, Children
Register for Updates
Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
NCT05382299
Recruiting
The primary objective of this study is to compare the progression-free survival (PFS) between sacituzumab govitecan-hziy (SG) versus treatment of physician's choice (TPC) in participants with previously untreated, locally advanced, inoperable or metastatic triple-negative breast cancer whose tumors do not express programmed cell death ligand 1 (PD-L1) or in participants previously treated with anti-programmed cell death (ligand or protein) 1 (Anti-PD-(L)1) Agents in the early setting whose tumor... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/15/2025
Locations: Texas Oncology PA,901 West 38th Street, Austin, Texas +2 locations
Conditions: Triple Negative Breast Cancer, PD-L1 Negative
Register for Updates
A Phase 2b, Randomized, Double-blind, Active-controlled Study of Single Dose CVXGA Intranasal COVID-19 Vaccine in Adults
NCT06742281
Recruiting
The purpose of this trial is to assess the safety and relative efficacy of CVXGA (CVXGA50), a KP.2 containing vaccine, compared to COMIRNATY® (COVID-19 Vaccine, mRNA; 2024-2025 Formula), a currently approved COVID-19 vaccine in the prevention of symptomatic, RT-PCR-confirmed SARS-CoV-2 infection. The trial will enroll up to 10016 healthy participants.
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
05/14/2025
Locations: Avacare, Austin, Texas +2 locations
Conditions: COVID-19
Register for Updates
A Study of EPX-100 (Clemizole Hydrochloride) in Participants With Dravet Syndrome
NCT04462770
Recruiting
This is a multicenter, Phase 3, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of clemizole HCL (EPX-100) as adjunctive therapy in children and adult participants with Dravet syndrome.
Gender:
ALL
Ages:
2 years and above
Trial Updated:
05/13/2025
Locations: Child Neurology Consultants of Austin, Austin, Texas
Conditions: Dravet Syndrome
Register for Updates